Therapeutic antibody manufacturing requires expensive and complex production that keeps treatment costs high. Encoding antibodies with mRNA has the potential to circumvent many traditional antibody manufacturing challenges, significantly reducing cost and time to clinic. With new data illustrating preclinical feasibility, the approach has recently matured to a viable therapeutic option.
This webinar will outline an mRNA-LNP based platform and roadmap to encode and deliver therapeutic antibodies in vivo within a patient, using the standard-of-care anti-HER2 antibody Trastuzumab as a case study. It will show that mRNA-encoded antibodies are comparable to infused recombinant equivalents in terms of reaching appropriate therapeutic levels, as well as demonstrate in vitro and in vivo efficacy validation.
This proof-to-concept data aims to establish that mRNA-encoded therapeutic antibodies can provide an effective, alternate approach for solid tumor immunotherapy, unlocking a strategy to democratize and enhance patient access to biologics. The webinar will review the process of designing and delivering mRNA-encoded antibodies, as well as the benefits and challenges of the new approach.
Register today to learn about this new frontier in antibody production and get your questions answered by industry experts.
RegisterKey Learning Objectives
- Discover the possibilities of mRNA-encoded antibodies compared to traditional manufacturing.
- Learn how mRNA-encoded antibodies are designed and delivered.
- Understand the safety and efficacy validation of mRNA-encoded antibodies.
- Learn how mRNA encoding might accelerate your next antibody development project.
